Most Ozempic users gain 67% of the weight back within 1 year of stopping. Your doctor probably didn't mention this.

You're 8 months in. Down 28 pounds. Clothes fit. The bloodwork looks better. You're considering tapering off because Wegovy retails at $1,349-1,800/month at the list price (NovoCare Direct, Novo's self-pay program that nobody mentions, runs $349-499/mo) and your job changes insurance in October.

Read this first.

The Novo Nordisk-funded extension of the STEP-1 trial followed 327 semaglutide responders. After they stopped the drug at week 68, by week 120 they had regained 11.6 kg of the 17.3 kg they'd lost. That's 67% of the weight, back, in about a year.

The lifestyle interventions continued. The diet counseling continued. The exercise programs continued. Only the drug stopped.

The drug was doing the work.

What the regain data actually shows

Wilding JPH et al., Diabetes Obes Metab 2022. The official extension of STEP-1.

Original trial: 68 weeks of semaglutide 2.4mg/week. Mean weight loss: -17.3% of body weight. The headline result that put GLP-1s on every magazine cover.

Extension: trial participants stopped the drug. Continued the structured lifestyle program. By week 120 (one year off drug):

• Mean weight regained: 11.6 kg (~67% of the loss reversed)
• Cardiometabolic improvements (A1c, lipids, BP) reverted toward baseline
• Some participants regained all of it
• A small subset (~10%) maintained most of the loss

The interpretation matters. This isn't "the drug failed." This is "obesity is a chronic disease, and we treated it acutely."

Compare to high blood pressure. You take lisinopril for 5 years, your BP normalizes. You stop lisinopril. Your BP goes back up. Nobody says lisinopril failed. Lisinopril works while you're taking it.

GLP-1s appear to work the same way. The drug is not retraining a system. The drug is occupying receptor sites that, when vacated, return to prior signaling.

The mechanism, plainly

Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist. Plain English: it mimics a hormone your gut releases after meals.

That hormone signal does three things:

1. Slows gastric emptying — food sits in your stomach longer, you feel full longer
2. Acts on the hypothalamus appetite circuits — reduces "thinking about food" baseline
3. Improves pancreatic beta-cell response to glucose — the original diabetes use

The first two are why you eat less. They are not learned behaviors. They are pharmacological effects of an external molecule.

When you stop the drug, your endogenous GLP-1 returns to baseline (which is low — that's why you were susceptible to weight gain in the first place). The appetite circuits return to their pre-drug setpoint. You start eating like you used to eat.

The body is not stupid. It defends a setpoint. The drug temporarily moved the setpoint. Removing the drug restores the original setpoint.

What "chronic" actually costs

If GLP-1 is chronic medication — like blood pressure meds, like statins, like SSRIs — the cost calculation is different from "expensive 6-month detox."

A 30-year cost projection at age 40, two scenarios:

• Wegovy at retail list ($1,400/mo) × 12 × 30 = $504,000
• Wegovy via NovoCare Direct ($349/mo) × 12 × 30 = $125,640

That's the actual lifetime cost of staying on brand-name Wegovy at current US pricing, before any insurance offset. NovoCare is the option Novo doesn't advertise to people who already have insurance — it exists precisely because retail pricing isn't sustainable.

For most people on retail pricing, the math isn't real. Insurance won't cover it indefinitely. Self-pay won't sustain it. The natural endpoint of brand-Wegovy-at-list-price is "you stop, you regain."

This is where the maintenance dose math changes things.

Maintenance dose, not loading dose

The titration schedule for semaglutide is escalating:

• Weeks 1-4: 0.25mg
• Weeks 5-8: 0.5mg
• Weeks 9-12: 1mg
• Weeks 13-16: 1.7mg
• Week 17+: 2.4mg (maximum)

Most weight loss happens at the higher doses. Most appetite suppression happens at 1.7-2.4mg.

But maintenance — keeping weight off after you've reached your target — looks different. STEP-4 (Rubino 2021, JAMA 325:1414) randomized week-20 responders to either continue 2.4mg or switch to placebo. The continuation arm held the loss; the placebo-switch arm regained 6.9% of body weight within 48 weeks. Lower-dose maintenance (e.g., 1mg/week instead of 2.4mg) is plausible mechanistically but not directly studied at scale — the trial data shows "stay on full dose vs. stop," not "ramp down."

Oral semaglutide (Rybelsus and bioequivalent generics) maintains at 7-14mg daily. Injectable maintains at 1-2.4mg/week. Both routes deliver the same molecule; the cost spread across them is dramatic.

The math: LiberaCure-routed oral at $229/mo is ~6x cheaper than Wegovy retail. LiberaCure-routed injection at $43-95/mo is 14-31x cheaper than Wegovy retail. Both lanes deliver semaglutide; the cost gap is markup, not molecule. (The injection lane, when in stock, is the cheaper ride — the supply just runs more lumpy than the oral.)

This isn't an endorsement of the cheap option being right for you. It's an honest pricing of what "chronic" actually costs across tiers.

The metaphor: GLP-1 is glasses, not LASIK

You're nearsighted. You buy glasses. You wear them daily. You see clearly.

Nobody says "the glasses didn't work" when you take them off and the world goes blurry again. Glasses work while you're wearing them.

Most weight loss culture treats GLP-1 like LASIK — a procedure that fixes the underlying problem. It isn't. It's glasses for your appetite system. Take them off, the appetite goes back.

The question isn't "should I take Ozempic." The question is "am I prepared to wear these glasses for 20 years."

When stopping is the right answer

Three cases where tapering off is reasonable:

• Side effects you can't tolerate. Pancreatitis signal, severe GI distress, gallbladder symptoms. These are not "wait it out" — these are stop and reassess.
• You hit a goal that wasn't really weight. A1c normalized and you're now diet-and-exercise-controlled. BP off meds. Some people use GLP-1 as a 12-month catalyst to actually change food architecture and stay there. The data on this is thin (~10% in the STEP-1 extension), but it exists.
• You moved into a different chronic plan. Bariatric surgery, for example. Different mechanism, different cost curve.

If none of those apply and you stop because the retail pen costs $1,400 — you're going to regain. The drug isn't failing. The economics are. (And before tapering off entirely: price NovoCare Direct, oral generic, or injection generic. The "stop" decision and the "stop paying $1,400" decision are not the same decision.)

What we route in this lane

We route both: oral generic semaglutide (Sembolic, bioequivalent to Rybelsus) and injectable generic semaglutide pens (Noveltreat, same dose strengths as Wegovy — 0.25, 0.5, 1, 1.7, 2.4mg). Different absorption profile, different dose math; both work, different lanes.

Oral runs more stable in stock; injectable runs lumpy. Cold-chain and single-use device handling are real friction in the personal-import lane, which is why the injection supply moves in waves. If you need ironclad month-to-month continuity on injections, telehealth-routed Wegovy or compounded semaglutide solves that with a different cost curve. Be aware of that bias when reading what follows.

What to do this month

If you're considering stopping:

1. Read the Wilding 2022 paper. It's open access. The regain trajectory is graphed clearly.
2. Price the cheaper continuation lanes before tapering to zero — NovoCare Direct, oral generic, injection generic. The "I can't afford retail Wegovy" decision and the "I want to be off the drug" decision should be made separately, not collapsed into one.
3. If you do want lower-dose maintenance (1mg/week instead of 2.4mg), know the trial data isn't there — STEP-4 studied "stay on full dose vs. stop," not gradual taper. Lower-dose maintenance is something to discuss with whoever's prescribing, not assume.

If you're considering starting:

1. Treat it like starting an SSRI — chronic medication, multi-year horizon, exit ramp uncertainty.
2. Don't think of it as a 6-month sprint. The data does not support that framing.
3. Plan the maintenance dose pricing on day one, not month nine.

For reference on our lane: LiberaCure quotes 2 weeks standard shipping (2-4 weeks with customs variance), tracking active 24-48h after dispatch. Crypto-only checkout (BTC, USDT TRC-20, LTC, XMR, ETH via NOWPayments) — that's the operational choice that lets the markup tier sit where it does.

Reship once free if tracking shows lost in transit. Second reship also free. Crypto refund (BTC/ETH/USDT) on third failure. Email reply 24-48h ([email protected]) — no live chat, no phone.

A note on bias.

We route semaglutide orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Sembolic (oral, bioequivalent to Rybelsus) and Noveltreat (injectable pens, same dose strengths as Wegovy) are two of the products we ship in this category. So we have a financial reason to want this article to lead you toward "give it a try" — and to keep filling.

Read this with that in mind. The protocol above is what I'd tell a friend, not what maximizes reorder rate.

Sources:

• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564. PMID 35441470
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. (STEP-1 main result.)
• Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA 2021;325(14):1414-1425. (STEP-4, maintenance dose study.)
• Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984.
• Novo Nordisk Wegovy and Rybelsus product monographs, accessed April 2026.
• GoodRx Rybelsus pricing data, April 2026.

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.